Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics
... reach US$57.7 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Stimulant, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$47.7 ... Read More
-
Cystic Fibrosis Therapeutics
... at a CAGR of 15.2% over the analysis period 2024-2030. Medication, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$42.1 Billion by the end of the ... Read More
-
Narcolepsy Therapeutics
... CAGR of 7.1% over the analysis period 2024-2030. Narcolepsy with Cataplexy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.9 Billion by the end of the ... Read More
-
High Content Screening (HCS)
... 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$1.0 Billion by the end ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Plasma Protein Therapeutics
... at a CAGR of 4.8% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$9.3 Billion by the end of the ... Read More
-
Metabolomics
... 11.7% over the analysis period 2024-2030. Biomarker Discovery Application, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$3.3 Billion by the end of the analysis period. ... Read More
-
Cloud-Based Drug Discovery Platforms
... 2030, growing at a CAGR of 14.3% over the analysis period 2024-2030. Pharmaceutical Vendors End-Use, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$3.0 Billion by ... Read More
-
Legionella Control (UK) - Industry Report
... the most attractive acquisition opportunities • Analyse industry trends • Benchmark their own financial performance Using an exclusive methodology, a quick glance of this Legionella Control (UK) report will tell you the companies that have ... Read More
-
Vitiligo Therapeutics
... CAGR of 4.0% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.2 Billion by the end of the analysis period. ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Peptide Therapeutics
... CAGR of 4.3% over the analysis period 2024-2030. Innovative, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$29.9 Billion by the end of the analysis period. ... Read More
-
Nanosilver
... 14.5% over the analysis period 2024-2030. Healthcare & Life Sciences, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$3.5 Billion by the end of the analysis ... Read More
-
Organs-on-Chips
... 35.3% over the analysis period 2024-2030. Liver, one of the segments analyzed in the report, is expected to record a 36.6% CAGR and reach US$206.0 Billion by the end of the analysis period. Growth in ... Read More
-
Bovine Respiratory Disease Treatment
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Infertility Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis ... Read More
-
Dilated Cardiomyopathy Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$258.2 Million by ... Read More
-
Chronic Spontaneous Urticaria - Market Insight, Epidemiology, and Market Forecast - 2034
... projected to grow at a CAGR of more than 10%, driven by the introduction of innovative therapies such as remibrutinib (LOU064), TEZSPIRE (Tezepelumab), and Rilzabrutinib (SAR444671), as well as increased awareness and better diagnostic capabilities. ... Read More
-
Acromegaly- Market Insight, Epidemiology, and Market Forecast - 2034
... ~USD 300 million, followed by growth hormone antagonist, i.e., ~USD 90 million in EU4 and the UK. The highest Acromegaly market was accounted by US which was ~ 55% of 7MM. Acromegaly is a rare ... Read More
-
Alzheimer's Disease - Market Insight, Epidemiology, and Market Forecast - 2034
... on healthcare systems and patient care. In 2023, among the EU4 and the UK, Germany accounted for the highest diagnosed prevalent cases of Alzheimer’s disease, representing 30% of the total cases, followed by France (24%). ... Read More
-
Ewing Sarcoma - Market Insight, Epidemiology, and Market Forecast - 2034
... because most Ewing sarcoma Patients are under 20 years old. Although there is no standardized second-line treatment for refractory or relapsed Ewing sarcoma, several retrospective studies have reported on conventional salvage treatments. Chemotherapy and local ... Read More
-
Epidermolysis Bullosa - Market Insight, Epidemiology, and Market Forecast - 2034
... (EBS) is the least severe type of epidermolysis bullosa, and many individuals with EBS may experience improvements as they age. On the other hand, recessive dystrophic epidermolysis bullosa is considered the most critical. Among the ... Read More
-
Heparin-induced Thrombocytopenia - Market Insight, Epidemiology, and Market Forecast - 2034
... the initiation of heparin therapy. It is primarily caused by the formation of antibodies against platelet factor 4 (PF4) and heparin. The diagnosis of Heparin-induced thrombocytopenia is based on a combination of clinical assessment, laboratory ... Read More
Research Assistance
